Thank you. It's going to be so crazy when a credible source with followers endorses CTIX. Still can't fathom how that hasn't happened yet, but I feel it may come any day. Doesn't somebody know a boitech research analyst at one of the big houses that would see the story and agree it's worth talking about?
With P53/P21 data suggesting a dose response relationship, I'd think they'd be interested in going to more than once per week dosing. Would they accomplish this through a protocol change in Phase 1? Or would they be able to argue a slightly lower dose with greater frequency (allowing for a greater total dose) for a Phase 2 protocol? TIA.
Yes we have to remember how complicated designing trials are. With limited data and knowledge, you have to devise the protocols for treatment (how much? how often? how delivered? what kind of patient? what stage of disease? etc, etc......) And if something isn't right, it can tank the trial, and the company. Been known to happen ;)
BK, assuming the MAD is 350 and the MTD is 210, does the FDA allow a dosage somewhere between 210 and 350 in Phase 2? I thought it cannot be more than the MTD. TIA!
Market Data 
Markets 
AI
